292 related articles for article (PubMed ID: 25567841)
21. Immunogenicity and effectiveness of routine immunization with 1 or 2 doses of inactivated poliovirus vaccine: systematic review and meta-analysis.
Grassly NC
J Infect Dis; 2014 Nov; 210 Suppl 1(Suppl 1):S439-46. PubMed ID: 24634499
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial.
Estívariz CF; Jafari H; Sutter RW; John TJ; Jain V; Agarwal A; Verma H; Pallansch MA; Singh AP; Guirguis S; Awale J; Burton A; Bahl S; Chatterjee A; Aylward RB
Lancet Infect Dis; 2012 Feb; 12(2):128-35. PubMed ID: 22071249
[TBL] [Abstract][Full Text] [Related]
23. The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model.
Norton EB; Bauer DL; Weldon WC; Oberste MS; Lawson LB; Clements JD
Vaccine; 2015 Apr; 33(16):1909-15. PubMed ID: 25765967
[TBL] [Abstract][Full Text] [Related]
24. Analyzed immunogenicity of fractional doses of Sabin-inactivated poliovirus vaccine (sIPV) with intradermal delivery in rats.
Ma L; Cai W; Sun M; Cun Y; Zhou J; Liu J; Hu W; Zhang X; Song S; Jiang S; Liao G
Hum Vaccin Immunother; 2016 Dec; 12(12):3125-3131. PubMed ID: 27558963
[TBL] [Abstract][Full Text] [Related]
25. Protocol for a systematic review and meta-analysis of fractional dose compared with standard dose inactivated polio vaccination in children.
Mashunye TR; Ndwandwe DE; Dube KR; Shey M; Shelton M; Wiysonge CS
BMJ Open; 2019 Mar; 9(3):e023308. PubMed ID: 30852530
[TBL] [Abstract][Full Text] [Related]
26. [Immunogenicity and safety of a booster dose of inactivated polio vaccine].
Li XM; Zhang ZJ; Wang HH; Liu F; Zhang LW; Chu P; Xu Y; Zhang HR; Li J; Liu DL; Lu L
Zhonghua Yu Fang Yi Xue Za Zhi; 2013 Oct; 47(10):905-9. PubMed ID: 24378129
[TBL] [Abstract][Full Text] [Related]
27. Determination of Depth-Dependent Intradermal Immunogenicity of Adjuvanted Inactivated Polio Vaccine Delivered by Microinjections via Hollow Microneedles.
Schipper P; van der Maaden K; Romeijn S; Oomens C; Kersten G; Jiskoot W; Bouwstra J
Pharm Res; 2016 Sep; 33(9):2269-79. PubMed ID: 27317570
[TBL] [Abstract][Full Text] [Related]
28. Diphtheria, tetanus and poliovirus antibody persistence 5 years after vaccination of pre-schoolers with two different diphtheria, tetanus and inactivated poliomyelitis vaccines (Td-IPV or DT-IPV) and immune responses to a booster dose of DTaP-IPV.
Gajdos V; Vidor E; Richard P; Tran C; Sadorge C
Vaccine; 2015 Jul; 33(32):3988-96. PubMed ID: 26087294
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity, safety, and antibody persistence at 3, 5, and 10 years postvaccination in adolescents randomized to booster immunization with a combined tetanus, diphtheria, 5-component acellular pertussis, and inactivated poliomyelitis vaccine administered with a hepatitis B virus vaccine concurrently or 1 month apart.
Embree J; Law B; Voloshen T; Tomovici A
Clin Vaccine Immunol; 2015 Mar; 22(3):282-90. PubMed ID: 25540274
[TBL] [Abstract][Full Text] [Related]
30. Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque.
Edens C; Dybdahl-Sissoko NC; Weldon WC; Oberste MS; Prausnitz MR
Vaccine; 2015 Sep; 33(37):4683-90. PubMed ID: 25749246
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and safety of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccine (Tdap-IPV; Repevax) administered concomitantly versus non-concomitantly with an influenza vaccine (Vaxigrip) to adults aged ≥60 years: an open-label, randomised trial.
Zimmermann U; Gavazzi G; Richard P; Eymin C; Soubeyrand B; Baudin M
Vaccine; 2013 Mar; 31(11):1496-502. PubMed ID: 23313654
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study.
John T; Voysey M; Yu LM; McCarthy N; Baudin M; Richard P; Fiquet A; Kitchin N; Pollard AJ
Vaccine; 2015 Aug; 33(36):4579-85. PubMed ID: 26165918
[TBL] [Abstract][Full Text] [Related]
33. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia.
Clarke E; Saidu Y; Adetifa JU; Adigweme I; Hydara MB; Bashorun AO; Moneke-Anyanwoke N; Umesi A; Roberts E; Cham PM; Okoye ME; Brown KE; Niedrig M; Chowdhury PR; Clemens R; Bandyopadhyay AS; Mueller J; Jeffries DJ; Kampmann B
Lancet Glob Health; 2016 Aug; 4(8):e534-47. PubMed ID: 27364568
[TBL] [Abstract][Full Text] [Related]
34. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
[TBL] [Abstract][Full Text] [Related]
35. Dose-sparing effect of Sabin-derived inactivated polio vaccine produced in Japan by intradermal injection device for rats.
Itoh E; Shimizu S; Ami Y; Iwase Y; Someya Y
Biologicals; 2023 May; 82():101677. PubMed ID: 37031619
[TBL] [Abstract][Full Text] [Related]
36. Randomized trial of inactivated and live polio vaccine schedules in Guatemalan infants.
Asturias EJ; Dueger EL; Omer SB; Melville A; Nates SV; Laassri M; Chumakov K; Halsey NA
J Infect Dis; 2007 Sep; 196(5):692-8. PubMed ID: 17674310
[TBL] [Abstract][Full Text] [Related]
37. One-Year Decline of Poliovirus Antibodies Following Fractional-Dose Inactivated Poliovirus Vaccine.
Saleem AF; Mach O; Yousafzai MT; Kazi Z; Baig A; Sajid M; Jeyaseelan V; Sutter RW; Zaidi AKM
J Infect Dis; 2021 Apr; 223(7):1214-1221. PubMed ID: 32798224
[TBL] [Abstract][Full Text] [Related]
38. Immune response to intradermally injected inactivated poliovirus vaccine.
Samuel BU; Cherian T; Sridharan G; Mukundan P; John TJ
Lancet; 1991 Aug; 338(8763):343-4. PubMed ID: 1677699
[TBL] [Abstract][Full Text] [Related]
39. First-in-human safety and immunogenicity investigations of three adjuvanted reduced dose inactivated poliovirus vaccines (IPV-Al SSI) compared to full dose IPV Vaccine SSI when given as a booster vaccination to adolescents with a history of IPV vaccination at 3, 5, 12months and 5years of age.
Lindgren LM; Tingskov PN; Justesen AH; Nedergaard BS; Olsen KJ; Andreasen LV; Kromann I; Sørensen C; Dietrich J; Thierry-Carstensen B
Vaccine; 2017 Jan; 35(4):596-604. PubMed ID: 28027810
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age.
Bravo LC; Carlos JC; Gatchalian SR; Montellano MEB; Tabora CFCB; Thierry-Carstensen B; Tingskov PN; Sørensen C; Wachmann H; Bandyopadhyay AS; Nielsen PI; Kusk MV
Vaccine; 2020 Jan; 38(3):530-538. PubMed ID: 31703934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
